Phuturdex › Diseases › Mesothelioma
Drugs in development · updated 30 October 2026
Mesothelioma: drugs in development
As of 30 October 2026 there are 42 active clinical trials (recruiting or ongoing, phases I–III) on 54 drugs for mesothelioma. 26 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| VT3989 | III | 2 | NCT07824986 |
| VolrustomigMEDI5752 | III | 1 | NCT06097728 |
| [18F]FAPI-74 | I–II | 2 | NCT07705074 |
| Iparomlimabiparomilimab | I–II | 2 | NCT07131345 |
| BMS-986504 | II | 1 | NCT07602946 |
| MDX2001 | I–II | 1 | NCT06239194 |
| ODM-212 | I–II | 1 | NCT07563738 |
| SpartalizumabPDR001 | II | 1 | NCT04802876 |
| TNG462 | I–II | 1 | NCT05732831 |
| Tuvonralimab | I–II | 1 | NCT07131345 |
| Tuvoraleimab injection | II | 1 | NCT07514793 |
| UV1 vaccine | II | 1 | NCT04300244 |
| VMD-928 Tablet | I–II | 1 | NCT03556228 |
| AG-01 Compound | I | 1 | NCT05627960 |
| BGC515 | I | 1 | NCT06452160 |
| HFB200301 | I | 1 | NCT05238883 |
| IAG933 | I | 1 | NCT04857372 |
| IDE397 | I | 1 | NCT07277413 |
| IDE892 | I | 1 | NCT07277413 |
| KFA115 | I | 1 | NCT05544929 |
| MRTX1719 | I | 1 | NCT05245500 |
| NGM438 | I | 1 | NCT05215574 |
| NGM831 | I | 1 | NCT05215574 |
| NXP900 | I | 1 | NCT05873686 |
| RoginolisibIOA-244 | I | 1 | NCT04328844 |
| KT032 | Early I | 1 | NCT07420010 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| NivolumabOpdivo, ONO-4538 | III | 7 | NCT06097728 |
| PemetrexedAxtle®, Pemfexy® | III | 7 | NCT06097728 |
| CarboplatinCarboplatine, Paraplatin | III | 6 | NCT06097728 |
| CisplatinCis Platinum, Cisplatine | III | 6 | NCT06097728 |
| IpilimumabYERVOY, ipililumab IV | III | 6 | NCT06097728 |
| AtezolizumabTecentriq, MPDL3280A | III | 2 | NCT04996017 |
| GemcitabineGemcitabin, Gemzar | III | 2 | NCT07824986 |
| VinorelbineNavelbine® | III | 1 | NCT07824986 |
| PembrolizumabKEYTRUDA, MK-3475 | I–II | 7 | NCT05579366 |
| CyclophosphamideCyclophosphamid, Cytoxan | I–II | 5 | NCT02414269 |
| FludarabineFludara, FLUDARABIN | I–II | 4 | NCT07510815 |
| Bevacizumabavastin, MVASI | I–II | 2 | NCT05579366 |
| TislelizumabTisleizumab, Tiselizumab | II | 2 | NCT04802876 |
| 18F-FDG^1^8F-fluorodeoxyglucose, Fludeoxyglucose F-18 | II | 1 | NCT06503146 |
| CedazuridineCedaruridine | II | 1 | NCT05960773 |
Sorted by most advanced phase and number of active trials. Showing 15 of 28 drugs.
All 54 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Malignant mesothelioma 58 drugs
- Neoplasm 671 drugs
- Metastasis 493 drugs
- Non-small-cell lung carcinoma 726 drugs
- Renal cell carcinoma 228 drugs
- Colorectal neoplasm 534 drugs
- Uterine cervix neoplasm 224 drugs
- Ovarian neoplasm 411 drugs
- Triple-negative breast neoplasm 334 drugs
- Stomach neoplasm 340 drugs
- Merkel cell carcinoma 48 drugs
- Esophageal neoplasm 191 drugs
Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Adenoma 4 drugs
- Neoplasm 671 drugs
- Lung disease 104 drugs
- Respiratory disease 57 drugs
- Respiratory tract neoplasm 21 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008654 “Mesothelioma”.